Primary Myelofibrosis Pipeline Insight and Clinical Trial Phases Report | 55+ Companies and 55+ Drugs | DelveInsight

DelveInsight's, "Primary Myelofibrosis Pipeline Insight, 2023" report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Primary Myelofibrosis pipeline landscape. It covers the Primary Myelofibrosis pipeline drug profiles, including Primary Myelofibrosis clinical trial and nonclinical stage products. It also covers the Primary Myelofibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Primary Myelofibrosis Pipeline Report

• DelveInsight's Primary Myelofibrosis pipeline report depicts a robust space with 55+ active players working to develop 55+ pipeline therapies for Primary Myelofibrosis treatment.

• The leading Primary Myelofibrosis Companies are working to develop drug candidates to improve Primary Myelofibrosis Treatment landscape include Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, Pharmaxis, MorphoSys, Merck & Co, AbbVie, Suzhou Zelgen Biopharmaceuticals, Geron Corporation, Keros Therapeutics, Galecto, Telios Pharma, Chia Tai Tianqing Pharmaceutical Group, Imago BioSciences, Roche, Incyte Corporation, Disc Medicine, Inc, Bristol-Myers Squibb, Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, Actuate Therapeutics, Samus Therapeutics, Karyopharm Therapeutics, and others.

• Promising Primary Myelofibrosis Pipeline Therapies in various stages of development include NS 018, KRT-232, TP 3654, PXS 5505, Pelabresib, ACE-536, Navitoclax, Jaktinib, Imetelstat, KER-050, GB 2064, TL-895, TQ05105, Bomedemstat, RO7490677, INCB000928, LDE225, DISC-0974, BMS-986158, BMS 986416, LNK01002, PU-H71, TBX-2400, CK0804, ABBV-744, JAB-8263, Tasquinimod, Mivebresib, 9-ING-41, Itacitinib, PU-H-71, Selinexor, and others.

• The Primary Myelofibrosis Companies and academics are working to assess challenges and seek opportunities that could influence Primary Myelofibrosis R&D. The Primary Myelofibrosis pipeline therapies under development are focused on novel approaches to treat/improve Primary Myelofibrosis.

Explore more about the latest breakthroughs of Primary Myelofibrosis Treatment Landscape and Primary Myelofibrosis Pipeline Outlook Report @ https://www.delveinsight.com/sample-request/primary-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Primary Myelofibrosis Overview

Primary Myelofibrosis (also called chronic idiopathic myelofibrosis, agnogenic myeloid metaplasia) is a disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. Over time, this leads to progressive bone marrow failure. Under normal conditions, the bone marrow provides a fine network of fibres on which the stem cells can divide and grow. Specialized cells in the bone marrow known as fibroblasts make these fibres. In primary myelofibrosis, chemicals released by high numbers of platelets and abnormal megakaryocytes (platelet forming cells) over-stimulate the fibroblasts. This results in the overgrowth of thick coarse fibres in the bone marrow, which gradually replace normal bone marrow tissue. Over time this destroys the normal bone marrow environment, preventing the production of adequate numbers of red cells, white cells and platelets. This results in anaemia, low platelet counts and the production of blood cells in areas outside the bone marrow for example in the spleen and liver, which become enlarged as a result. Primary myelofibrosis is a rare chronic disorder diagnosed in an estimated 1 per 100,000 population. It can occur at any age but is usually diagnosed later in life, between the ages of 60 and 70 years.

Recent Developmental Activities in the Primary Myelofibrosis Treatment Landscape

• In June 2022, Cellenkos announced that the US Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application to initiate a Phase Ib, open-label study of CK0804 as an add-on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib.

• In June 2022, Imago Biosciences presented updated positive data from its ongoing global Phase II clinical study evaluating bomedemstat in patients with advanced myelofibrosis. Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis.

• In June 2022, announced the US FDA granted Orphan Drug Designation for TP-3654, Sumitomo Pharma Oncology's proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis.

• In June 2022, AbbVie announced new data from Cohort 3 of its Phase II REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF), a rare and difficult to treat blood cancer. These data reinforced the importance of early intervention in myelofibrosis and the potential to achieve improved clinical outcomes.

• In February 2022, Active Biotech entered into an exclusive license agreement with Oncode Institute in the Netherlands for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in the treatment of myelofibrosis.

To discover the recent advances in Primary Myelofibrosis Treatment Drugs, visit Primary Myelofibrosis Ongoing Clinical Trials @ https://www.delveinsight.com/sample-request/primary-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Primary Myelofibrosis Emerging Drugs Profile

NS 018: Nippon Shinyaku
Ilginatinib (formerly NS 018), a potent inhibitor of Janus kinase 2 (JAK2) enzyme activity and Src-family kinases is being developed by Nippon Shinyaku.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Primary Myelofibrosis.

KRT-232: Kartos Therapeutics
Navtemadlin (KRT-232), is a novel, potent and selective oral MDM2 inhibitor. The MDM2-p53 interaction represents a compelling therapeutic target with potential to provide a new treatment option for patients with Myelofibrosis (MF), Polycythemia Vera (PV), Acute Myeloid Leukemia (AML), and Merkel Cell Carcinoma (MCC).Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Primary Myelofibrosis.

TP 3654: Sumitomo Pharma Oncology
TP-3654 is an oral investigational inhibitor of PIM kinases, which has potential antitumor and anti-fibrotic effects through multiple pathways, including induction of apoptosis. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Primary Myelofibrosis.

Primary Myelofibrosis Therapeutics Assessment
There are approx. 55+ key companies which are developing the therapies for Primary myelofibrosis. The companies which have their Primary myelofibrosis drug candidates in the most advanced stage, i.e. Phase II/III include, Kartos Therapeutics.

Find out more about Primary Myelofibrosis Treatment Drugs and Primary Myelofibrosis Treatment Landscape @ https://www.delveinsight.com/report-store/primary-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Primary Myelofibrosis Pipeline Insight Report
• Coverage- Global

• Primary Myelofibrosis Companies- Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, Pharmaxis, MorphoSys, Merck & Co, AbbVie, Suzhou Zelgen Biopharmaceuticals, Geron Corporation, Keros Therapeutics, Galecto, Telios Pharma, Chia Tai Tianqing Pharmaceutical Group, Imago BioSciences, Roche, Incyte Corporation, Disc Medicine, Inc, Bristol-Myers Squibb, Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, Actuate Therapeutics, Samus Therapeutics, Karyopharm Therapeutics, and others.

• Primary Myelofibrosis Pipeline Therapies- NS 018, KRT-232, TP 3654, PXS 5505, Pelabresib, ACE-536, Navitoclax, Jaktinib, Imetelstat, KER-050, GB 2064, TL-895, TQ05105, Bomedemstat, RO7490677, INCB000928, LDE225, DISC-0974, BMS-986158, BMS 986416, LNK01002, PU-H71, TBX-2400, CK0804, ABBV-744, JAB-8263, Tasquinimod, Mivebresib, 9-ING-41, Itacitinib, PU-H-71, Selinexor, and others.

• Primary Myelofibrosis Segmentation: Phases, Molecule Type, Route of Administration, Mechanism of Action, Product Type

Table of Content
1. Introduction
2. Primary Myelofibrosis Executive Summary
3. Primary Myelofibrosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Primary Myelofibrosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase II/III)
8. KRT-232: Kartos Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. NS 018: Nippon Shinyaku
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Primary Myelofibrosis Key Companies
21. Primary Myelofibrosis Key Products
22. Primary Myelofibrosis- Unmet Needs
23. Primary Myelofibrosis- Market Drivers and Barriers
24. Primary Myelofibrosis- Future Perspectives and Conclusion
25. Primary Myelofibrosis Analyst Views
26. Primary Myelofibrosis Key Companies
27. Appendix

Learn more about the Primary Myelofibrosis Emerging Therapies and Primary Myelofibrosis Market Drivers and Barriers @ https://www.delveinsight.com/report-store/primary-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.